{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:05:59Z","timestamp":1777392359256,"version":"3.51.4"},"reference-count":169,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CS\/097\/2013"],"award-info":[{"award-number":["CS\/097\/2013"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SB\/FT\/CS\u2010100\/2013"],"award-info":[{"award-number":["SB\/FT\/CS\u2010100\/2013"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS\u2010CoV\u20102. Further, the complications related to drug\u2010resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available. Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re\u2010engineering old TB\u2010drug families and repurposing known drugs. These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug\u2010resistant\u00a0strains. With respect to this context, we discuss structural aspects of developing new anti\u2010TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future\u2010generation potent, yet safer anti\u2010TB drugs.<\/jats:p>","DOI":"10.1002\/ardp.202200214","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T20:50:16Z","timestamp":1657918216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Drug re\u2010engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery"],"prefix":"10.1002","volume":"355","author":[{"given":"Dinesh S.","family":"Reddy","sequence":"first","affiliation":[{"name":"Centre for Nano and Material Sciences, Jain University Bangalore India"}]},{"given":"Anamika","family":"Sinha","sequence":"additional","affiliation":[{"name":"Centre for Nano and Material Sciences, Jain University Bangalore India"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9760-6233","authenticated-orcid":false,"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Centre for Nano and Material Sciences, Jain University Bangalore India"}]},{"given":"Vipin K.","family":"Saini","sequence":"additional","affiliation":[{"name":"Materials and Environmental Chemistry Research Laboratory, School of Environment &amp; Natural Resources Doon University Dehradun India"}]}],"member":"311","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health Organization Global tuberculosis report 2019.https:\/\/www.who.int\/publications\/i\/item\/9789241565714. (accessed: June 2021)."},{"key":"e_1_2_8_3_1","unstructured":"World Health Organization Global tuberculosis report 2021.https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2021. (accessed: June 2022)."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.03.042"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2020.101989"},{"key":"e_1_2_8_5_1","unstructured":"(a)TBFACTS.ORG Information about tuberculosis; 2021.\u00a0https:\/\/tbfacts.org\/second-line-drugs. (accessed: September 2021)"},{"key":"e_1_2_8_5_2","unstructured":"(b) World Health Organization.\u00a0Global tuberculosis report; 2020.https:\/\/www.who.int\/publications\/i\/item\/9789240013131. (accessed: December 2021)."},{"key":"e_1_2_8_6_1","unstructured":"(a)TB Alliance Inadequate Treatment Today's TB medicines are inadequate to tackle the TB pandemic. New treatments that are faster simpler and affordable are urgently needed; 2021.\u00a0https:\/\/www.tballiance.org\/why-new-tb-drugs\/inadequate-treatment. (accessed: September 2021)"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01833"},{"key":"e_1_2_8_7_1","unstructured":"World Health Organization. TB\/HIV key facts and figures fact sheet on tuberculosis.\u00a0https:\/\/www.who.int\/3by5\/TBfactsheet.pdf. (accessed: September 2021)."},{"key":"e_1_2_8_8_1","unstructured":"(a)World Health Organization. HIV\u2010associated tuberculosis; 2018.\u00a0https:\/\/www.who.int\/tb\/areas-of-work\/tb-hiv\/tbhiv_factsheet.pdf. (accessed: September 2021)"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09657"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.10.20033795"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2020.07.003"},{"key":"e_1_2_8_9_3","unstructured":"(c) World Health Organization WHO\u00a0information note: Tuberculosis and COVID\u201019;2020. (accessed: September 2021)"},{"key":"e_1_2_8_9_4","unstructured":"(d) Stop TB Partnership. The potential impact of the COVID\u201019 response on tuberculosis in high\u2010burden countries: A modelling analysis. Dev by Stop TB Partnersh Collab with Imp CollAvenir Heal Johns Hopkins Univ USAID;2020. (accessed: January 2022)."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.06.056"},{"key":"e_1_2_8_10_2","first-page":"576","volume":"2","author":"Hosamani K. M.","year":"2015","journal-title":"Eur. J. Biomed. Pharm. Sci."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00255"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37562017000000436"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54849-w"},{"key":"e_1_2_8_14_1","unstructured":"(a) Working group on new TB drugs stop TB partnership;2020.https:\/\/www.newtbdrugs.org\/pipeline\/clinical. (accessed: September 2021)"},{"key":"e_1_2_8_14_2","unstructured":"(b) L.McKenna TAG the 2020 tuberculosis treatment pipeline report"},{"key":"e_1_2_8_14_3","unstructured":"(c) D.Barros\u2010Aguirre G.Koh Tuberculosis research unit\u2014Pipeline update\u00a0Presented to the Global TB Community Advisory Board (TB CAB);2020."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70328-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.031"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05749-2"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.03.007"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.15"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.08.001"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2016.10.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02452"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.95"},{"key":"e_1_2_8_23_2","volume-title":"Drug Repurposing for Tuberculosis","author":"Cardoso N. C.","year":"2021"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rppnen.2017.10.009"},{"key":"e_1_2_8_25_1","unstructured":"TB Alliance. Pretomanid; 2021.https:\/\/www.tballiance.org\/portfolio\/compound\/pretomanid. (accessed: September 2021)."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S281639"},{"key":"e_1_2_8_27_1","unstructured":"Delamanid\u2014Wikipedia.https:\/\/en.wikipedia.org\/wiki\/Delamanid"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.717045"},{"key":"e_1_2_8_29_1","unstructured":"L.McKenna Treatment action group (TAG) the tuberculosis treatment pipeline;\u00a02019. (accessed: September 2021)."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050461"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.03.031"},{"key":"e_1_2_8_31_2","volume-title":"Stat Pearls","author":"Suresh A. B.","year":"2022"},{"key":"e_1_2_8_32_1","unstructured":"ClinicalTrials.gov. Bethesda: National Library of Medicine (US); 2000. IdentifierNCT02410772. TBTC Study 31: Rifapentine\u2010containing Tuberculosis Treatment Shortening Regimens (S31\/A5349).http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02410772?term=rifapentine%2Bmoxifloxacin%26rank=4. (accessed: September 2021)."},{"key":"e_1_2_8_33_1","unstructured":"Rifabutin. The American Society of Health\u2010System Pharmacists; 2016."},{"key":"e_1_2_8_34_1","unstructured":"ClinicalTrials.gov. US National Library of Medicine Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex; 2021.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03164291. (accessed: September 2021)."},{"key":"e_1_2_8_35_1","volume-title":"Faculty of Economics","author":"Hara Y.","year":"2019"},{"key":"e_1_2_8_36_1","volume-title":"StatPearls","author":"Graham D. B.","year":"2022"},{"key":"e_1_2_8_37_1","unstructured":"US Patent 5053407;2016https:\/\/web.archive.org\/web\/20160827002405\/ http:\/\/www.fr.com\/files\/Uploads\/attachments\/memoranda\/memorANDAQ209.pdf. (accessed: March 2021)."},{"key":"e_1_2_8_38_1","unstructured":"S.Atarashi Research and Development of Quinolones. Daiichi Sankyo Co. https:\/\/www.semanticscholar.org\/paper\/Research-and-Development-of-Quinolones-in-Daiichi-Atarashi\/e9e47145b29b4bde46a8775f90ad988f209d3e77. (accessed: September 2021)."},{"key":"e_1_2_8_39_1","unstructured":"M.Frick A.Gaudino M.Harrington T.Horn R.Jefferys J.Johnson E.Lessem M.Low L.McKenna Pipeline report HIV TB & HCV drugs diagnostics vaccines preventive technologies cure research and immune\u2010based and gene therapies in development; 2017. Treatment Action Group. (accessed: March 2022)."},{"key":"e_1_2_8_40_1","unstructured":"Levofloxacin\u2014Wikipedia.https:\/\/en.wikipedia.org\/wiki\/Levofloxacin. (accessed: April 2022)."},{"key":"e_1_2_8_41_1","unstructured":"Moxifloxacin hydrochloride. The American Society of Health\u2010System Pharmacists;2017."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900040"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.968"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.166599"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02329-2017"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900135"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315817"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0884"},{"key":"e_1_2_8_50_1","unstructured":"Sparfloxacin\u2014Wikipedia.https:\/\/en.wikipedia.org\/wiki\/Sparfloxacin. (accessed: April 2022)."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2016.07.008"},{"key":"e_1_2_8_52_1","first-page":"21","volume":"53","author":"Sokolova G.","year":"2008","journal-title":"Antibiot. Chemoter."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00283-1"},{"key":"e_1_2_8_53_2","first-page":"e89","volume":"4","author":"Andrews J.","year":"2016","journal-title":"Global\u00a0Health"},{"key":"e_1_2_8_54_1","unstructured":"AstraZeneca. New tuberculosis drug trial begins in South Africa; 2019.\u00a0http:\/\/www.astrazeneca.com\/Research\/news\/Article\/20121210-new-tuberculosisdrug-trial-begins-in-south-africa. (accessed: April 2019)."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01903-13"},{"key":"e_1_2_8_56_1","unstructured":"Working Group for New TB Drugs Delpazolid (LCB01\u20100371).https:\/\/www.newtbdrugs.org\/pipeline\/compound\/delpazolid-lcb01-0371. (accessed: September 2021)."},{"key":"e_1_2_8_57_1","unstructured":"Working Group for New TB Drugs TBI\u2010223.https:\/\/www.newtbdrugs.org\/pipeline\/compound\/tbi-223. (accessed: September 2021)."},{"key":"e_1_2_8_58_1","unstructured":"World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization Geneva2019."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009939"},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","unstructured":"Y.Qin L. L.Zhang Y. R.Ye Y. T.Chen Z.Jiao Br. J. Clin. Pharmacol.2022.https:\/\/doi.org\/10.1111\/bcp.15368.","DOI":"10.1111\/bcp.15368"},{"key":"e_1_2_8_61_1","first-page":"CD012836","volume":"3","author":"Singh B.","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_62_1","volume-title":"WHO Consolidated Guidelines on Drug\u2010Resistant Tuberculosis Treatment (WHO\/CDS\/TB\/2019.7)","author":"World Health Organization","year":"2019"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.06.020"},{"key":"e_1_2_8_64_1","unstructured":"Ethambutol Hydrochloride. The American Society of Health\u2010System Pharmacists;2016."},{"key":"e_1_2_8_65_1","unstructured":"R. H.Drew UpToDate;2022.https:\/\/www.uptodate.com\/contents\/ethambutol-an-overview. (accessed: February 2022)."},{"key":"e_1_2_8_66_1","unstructured":"Working Group for New TB Drugs SQ109 Stop TB Partnership.https:\/\/www.newtbdrugs.org\/news\/press-release-infectex-and-sequella-sq-109-clinical-trialrussia. (accessed: September 2021)."},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119301"},{"key":"e_1_2_8_68_1","unstructured":"US\u00a0Food and Drug Administration approves Gilead's antiviral veklury (remdesivir) for treatment of COVID\u201019. Gilead Sciences Inc;2020."},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2020.40"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2011.10.002"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.12.004"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008489"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3314"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.164"},{"key":"e_1_2_8_73_1","unstructured":"Clofazimine. The American Society of Health\u2010System Pharmacists; 2016."},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.11.010"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.03.050"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22071171"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.06.023"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133183"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof7020067"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2006.00350.x"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2006.00224.x"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.07.028"},{"key":"e_1_2_8_82_1","first-page":"239","volume":"3","author":"Ahmad Z.","year":"2007","journal-title":"Biol. Med."},{"key":"e_1_2_8_83_1","unstructured":"Meropenem. The American Society of Health\u2010System Pharmacists;2017."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00124312"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167498"},{"key":"e_1_2_8_86_1","unstructured":"ClinicalTrials.gov. Early bactericidal activity of rifampin + meropenem + amoxicillin\/clavulanate in adults with pulmonary TB.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03174184. (accessed: September 2021)."},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201800141"},{"key":"e_1_2_8_88_1","unstructured":"ClinicalTrials.gov. Metronidazole for pulmonary tuberculosis (South Korea);2013.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00425113. (accessed: September 2021)."},{"key":"e_1_2_8_89_1","unstructured":"M.Johnson Metronidazole: An overview UpToDate;2022.https:\/\/www.uptodate.com\/contents\/metronidazole-an-overview. (accessed: July 2022)."},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics6010003"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00649-2015"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2014.09.001"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldw019"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214188109"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00772"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz018"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06445-11"},{"key":"e_1_2_8_98_1","unstructured":"H.Koester L. V.Kleist S.Michaelis K.Bartho M.Schlief M.Dreger A. K.Schrey M.Sefkow F.Kroll D.Ohlendorf Y.Luo Patent Number: 11008282 2016."},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa307"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2014.02.009"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.01.078"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.04.012"},{"key":"e_1_2_8_103_1","first-page":"CD004795","volume":"6","author":"Ziganshina L. E.","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.1.94"},{"key":"e_1_2_8_105_1","doi-asserted-by":"crossref","first-page":"e6178","DOI":"10.1002\/aoc.6178","volume":"35","author":"El\u2010Shwiniy W. H.","year":"2021","journal-title":"Appl. Organomet. Chem."},{"key":"e_1_2_8_106_1","unstructured":"Working group on new TB drugs contezolid stop TB partnership.https:\/\/www.newtbdrugs.org\/pipeline\/compound\/contezolid-mrx-4mrx-1. (accessed: September 2021)."},{"key":"e_1_2_8_107_1","unstructured":"MicuRx Pharmaceuticals Inc. Project progress.http:\/\/micurxchina.com\/project. (accessed: January 2019)."},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01576-0"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00493-18"},{"key":"e_1_2_8_110_1","unstructured":"Metformin Hydrochloride. The American Society of Health\u2010System Pharmacists; 2017."},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0828-9"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13371"},{"key":"e_1_2_8_112_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4548-4"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00435"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0443-y"},{"key":"e_1_2_8_115_1","first-page":"e02516","volume":"63","author":"Sarathy J.","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.4430"},{"key":"e_1_2_8_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000232"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.201903763"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000180"},{"key":"e_1_2_8_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00706-021-02806-7"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1043-y"},{"key":"e_1_2_8_119_2","unstructured":"(b) Quinolone Antibiotic\u2014Wikipedia.https:\/\/en.wikipedia.org\/wiki\/Quinolone_antibiotic. (accessed: May 2022)"},{"key":"e_1_2_8_119_3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfluchem.2018.01.007"},{"key":"e_1_2_8_120_1","doi-asserted-by":"crossref","unstructured":"Infectious diseases (Fourth Edition) section 7 anti\u2010infective therapy oxazolidinones Franklin D. Lowy;2017 2 1230\u20101232.","DOI":"10.1016\/B978-0-7020-6285-8.00142-8"},{"key":"e_1_2_8_121_1","first-page":"159285","volume":"2012","author":"Pandit N.","year":"2012","journal-title":"Int. J. Med. Chem."},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26144280"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2020.100201"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00068"},{"key":"e_1_2_8_124_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm501045e"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00500"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.07.049"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000002"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111887"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa136"},{"key":"e_1_2_8_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.06.007"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.90"},{"key":"e_1_2_8_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.183"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03551-w"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.06.068"},{"key":"e_1_2_8_134_1","unstructured":"World Health Organization. Rapid communication: key changes to treatment of multidrug\u2010and rifampicin\u2010resistant tuberculosis (MDR\/RR\u2010TB). WHO: Geneva Switzerland;2018."},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.08.001"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801246z"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.03.021"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.12.002"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00034"},{"key":"e_1_2_8_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.10.024"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.06.009"},{"key":"e_1_2_8_140_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_2_8_140_3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0241-5"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5RA09508E"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2020.102050"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133452"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.202200214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ardp.202200214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.202200214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T16:49:22Z","timestamp":1700844562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.202200214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":169,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/ardp.202200214"],"URL":"https:\/\/doi.org\/10.1002\/ardp.202200214","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"value":"0365-6233","type":"print"},{"value":"1521-4184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"2022-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2200214"}}